Clinical Validation

The following is an excerpt from our clinical studies published in 2018 in the Journal of Applied Laboratory Medicine.  View the full article.

“Extracellular MV-A iNOS is a novel plasma biomarker for the onset of sepsis and appears to be intimately involved in the initiation of the sepsis cascade by producing toxic quantities of NO in susceptible receiver cells in the heart and vascular system and that comprise barrier structures in the body. The discovery of plasma iNOS has led to advances in the development of a targeted therapy by identifying those individuals who would benefit from an anti-MV-A iNOS mAb therapeutic.”